Xencor

316 articles about Xencor

• Xencor Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 Congress

  5/30/2023

  Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today announced the presentation of results from its Phase 1a single-ascending dose study of XmAb®564 in healthy volunteers.

• Xencor Reports First Quarter 2023 Financial Results

  5/8/2023

  Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today reported financial results for the first quarter ended March 31, 2023 and provided a review of recent business and clinical highlights.

• Xencor to Host First Quarter 2023 Financial Results Webcast and Conference Call on May 8, 2023

  5/1/2023

  Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will release first quarter 2023 financial results after the market closes on Monday, May 8, 2023.

• Xencor Appoints Nancy Valente, M.D., as Chief Development Officer

  4/26/2023

  Xencor, Inc. today announced the appointment of Nancy Valente, M.D., to Executive Vice President, Chief Development Officer.

• Xencor Highlights CD28 Bispecific Antibody Platform at AACR Annual Meeting 2023

  4/17/2023

  Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today presented new preclinical data generated from engineered CD28 bispecific antibodies targeting the solid tumor antigens CEACAM5, ENPP3, mesothelin, STEAP1 and Trop-2.

• Xencor to Present Preclinical Data from Novel XmAb® CD28 Bispecific Antibody Programs at the American Association for Cancer Research Annual Meeting 2023

  3/14/2023

  Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will present preclinical data on novel XmAb® CD28 bispecific antibody programs at the American Association for Cancer Research (AACR) Annual Meeting, being held April 14-19, 2023 at the Orange County Convention Center in Orlando, Florida.

• Xencor Reports Fourth Quarter and Full Year 2022 Financial Results

  2/23/2023

  Xencor, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a review of recent business and clinical highlights.

• Xencor to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023

  2/16/2023

  Xencor, Inc. announced that it will report financial results for the fourth quarter and full year 2022 after the market closes on Thursday, February 23, 2023.

• Xencor to Present at the SVB Securities Global Biopharma Conference

  2/7/2023

  Xencor, Inc. (NASDAQ:XNCR) today announced that company management will present at the virtual 2023 SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023, at 3:40 p.m. ET / 12:40 p.m. PT.

• Atreca and Xencor to Develop T Cell Engaging Bispecific Antibody Directed Against Novel Solid Tumor Target

  2/6/2023

  Atreca, Inc. (Atreca) (NASDAQ: BCEL) and Xencor, Inc. (NASDAQ: XNCR) today announced, as part of their existing strategic collaboration, they have mutually selected the first program combining an Atreca-discovered antibody with Xencor’s XmAb® bispecific Fc domain and a cytotoxic T-cell binding domain (CD3).

• Xencor Highlights 2023 Corporate Priorities and Provides Portfolio Updates

  1/9/2023

  Xencor, Inc. today announced 2023 corporate priorities and provided multiple clinical development updates.

• Xencor to Present at the 41st Annual J.P. Morgan Healthcare Conference

  1/4/2023

  Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023 at 3:45 p.m. PST.

• Xencor Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma at the American Society of Hematology Annual Meeting

  12/12/2022

  Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced additional clinical data from expansion cohorts in its Phase 1 study of plamotamab, a CD20 x CD3 bispecific antibody, in patients with relapsed or refractory non-Hodgkin lymphomas.

• Xencor Presents Early Clinical Data from Combination Study of Vudalimab and New Data from Multiple Preclinical-stage XmAb® Programs at the SITC Annual Meeting

  11/10/2022

  Xencor Presents Early Clinical Data from Combination Study of Vudalimab and New Data from Multiple Preclinical-stage XmAb ® Programs at the SITC Annual Meeting.

• Xencor to Present at Upcoming November 2022 Investor Conferences

  11/10/2022

  Xencor, Inc. announced that company management will participate at two upcoming investor conferences.

• Xencor’s IL2-Fc Cytokine, XmAb®564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical Study

  11/7/2022

  Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced topline clinical data from its Phase 1a single-dose, healthy volunteer study of XmAb®564, in development for patients with autoimmune diseases.

• Xencor Reports Third Quarter 2022 Financial Results

  11/7/2022

  Xencor, Inc. reported financial results for the third quarter ended September 30, 2022 and provided a review of recent business and clinical highlights.

• Xencor to Present New Clinical Data from the Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin’s Lymphoma at the American Society of Hematology Annual Meeting

  11/3/2022

  Xencor, Inc. (NASDAQ: XNCR) today announced that clinical data from expansion cohorts in its Phase 1 study of plamotamab, a CD20 x CD3 bispecific antibody, in patients with relapsed or refractory non-Hodgkin’s lymphoma will be presented in a poster session during the 64th American Society of Hematology (ASH) Annual Meeting in New Orleans, Louisiana on Monday, December 12, 2022.

• Xencor to Host Third Quarter 2022 Financial Results Webcast and Conference Call on November 7, 2022

  10/31/2022

  Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will release third quarter 2022 financial results after the market closes on Monday, November 7, 2022.

• Xencor to Present Seven Posters on Multiple Clinical Trials and Research-stage Programs at the SITC Annual Meeting

  10/5/2022

  Xencor, Inc today announced seven poster presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer, being held in Boston, November 10-12, 2022.